By 2 decades, the majority with relapsing-remitting MS (RRMS) have secondary progressive MS (SPMS). SPMS pathophysiology likely involves mitochondrial dysfunction, microglial activation, vascular endothelial disruption, and effects of meningeal lymphoid-like tissues.^[@R1]^ The resulting neurodegeneration and accelerated brain atrophy correlate with functional disability; thus whole-brain atrophy is the current gold-standard MRI surrogate outcome measure for SPMS trials.^[@R2]^ Targeting specific pathophysiologic processes is a rational strategy for treating SPMS.

Lipoic acid (LA) is an endogenously produced antioxidant with multiple biological functions including free-radical scavenging, metallic ion chelation, regeneration of intracellular glutathione, and oxidative damage repair of macromolecules.^[@R3]^ In mitochondria, the LA/dihydrolipoic acid redox couple is a key cofactor for the pyruvate dehydrogenase complex of oxidative respiration and aids nucleic acid synthesis.^[@R4]^ LA modulates the PKB/Akt signaling pathway important for vascular endothelial integrity, affects transcription factor Nrf2, and acts as an insulin mimetic.^[@R5],[@R6]^

Our center and others have shown that LA reduced disability in experimental autoimmune encephalomyelitis (EAE), diminished inflammatory cell migration into spinal cords and optic nerves, and inhibited macrophage/microglial activation.^[@R7],[@R8]^ Oral ingestion of LA by patients with MS produced blood levels comparable with those in EAE.^[@R9]^ In clinical trials, LA is well tolerated; common adverse reactions were gastrointestinal (GI) intolerance, headache, malodorous urine, and rash.^[@R10],[@R11]^ Herein, we report results of a 2-year, randomized controlled trial to determine whether LA reduced rates of whole-brain atrophy, slowed clinical deterioration, and was safe in SPMS.

METHODS {#s1}
=======

Study design. {#s1-1}
-------------

This was a prospective, single-site, 2-year, phase II, double-blind, randomized, placebo-controlled trial of 1,200 mg daily oral racemic LA to answer the following primary research question with Class I level of evidence: would LA reduce the rate of whole-brain atrophy in SPMS? Secondary research questions were to determine whether LA would reduce rates of atrophy of segmented brain, spinal cord, and retinal substructures, reduce deterioration of disability and quality of life, and be safe in SPMS. Recruitment occurred between May 2011 and October 2013, with last visit being in August 2015. The study was conducted at the Veterans Affairs Portland Health Care System (VAPORHCS), Portland, OR, with some procedures at Oregon Health & Science University (OHSU), Portland, OR.

Participants. {#s1-2}
-------------

Inclusion criteria were ages 40--70 years, prior RRMS (2005 McDonald criteria), and current SPMS defined by MS disability progression in the absence of clinical relapse during the prior 5 years as determined by the principal investigator (PI) based on history and chart review.^[@R12]^ Progression was defined as sufficient to change a Functional System on the Expanded Disability Status Scale (EDSS) or effect a meaningful functional change (e.g., stopped working due to cognitive decline).^[@R13]^ Participants were permitted to start, stop, or continue glatiramer acetate or β-interferon during the study. Exclusion criteria were use of natalizumab, immunosuppressants, chemotherapies, or scheduled IV corticosteroid treatments within 1 year of enrollment, corticosteroid treatment for relapse within 60 days of enrollment, LA within 30 days of enrollment, MRI constraints, self-reported ocular disease that could confound optical coherence tomography (OCT) interpretation, pregnant or breastfeeding, significant active concurrent illness, uncontrolled or insulin-dependent diabetes, and lack of English fluency. Because of slow recruitment during the first 8 months, the EDSS limit of 6.0 was eliminated.

Standard protocol approvals, registrations, and patient consents. {#s1-3}
-----------------------------------------------------------------

The study was approved by VAPORHCS and OHSU Institutional Review Boards. Written consent was obtained from all the participants. The study was registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT01188811) and conducted following 2010 CONSORT guidelines.^[@R14]^

Study personnel roles. {#s1-4}
----------------------

The PI conducted screening visits and initial EDSS examinations for randomization, evaluated adverse events (AEs), and served as the study monitor. Blinded neurologists and a neurology advanced practitioner served as EDSS examiners. Blinded study coordinators collected mobility data, questionnaires, and maintained databases.

Investigational drug. {#s1-5}
---------------------

An Investigational New Drug indication was obtained by the PI (no. 110132). Pure Encapsulations (Sudbury, MA) provided gelatin capsules containing 600 mg racemic LA or placebo. Placebo capsules contained Avicel (microcellulose crystal) and 4.3 mg of quercetin (a bioflavonoid) that rendered the placebo a yellow color, similar to LA. Expiration of the study drug was extended once during the study by Pure Encapsulations after retesting of sample capsules determined continued stability.

Study timeline. {#s1-6}
---------------

Screen and baseline visits were ≤30 days apart. Subsequent visits at months 3, 6, 12, 18, and 24 occurred ±2 weeks. A month was defined as 4 weeks for scheduling purposes. MRI and OCT occurred at baseline, months 12 and 24. Clinical outcome measures were collected at baseline and every 6 months. Safety laboratory measures were performed at each visit. Telephone calls occurred between visits and after study completion to capture AEs.

Outcomes. {#s1-7}
---------

Primary outcome was difference in annual percent change brain volume (PCBV) on MRI by Structural Image Evaluation, using Normalisation, of Atrophy (SIENA). Secondary outcomes included atrophy rates of segmented brain, spinal cord, and retinal substructures, changes in disability, quality of life, and safety.

MRI acquisition protocol. {#s1-8}
-------------------------

MRI acquisition and analyses details are shown in appendix e-1 at [Neurology.org/nn](10.1212/NXI.0000000000000374). The following sequences were acquired using a Philips Achieva 3.0T X-series with Quasar Dual gradient systems: (1) 3D high-resolution magnetization-prepared rapid acquisition gradient echo (3D MP-RAGE) with 1 mm^3^ voxels for high-resolution structural (T1-weighted) information. The upper cervical spinal cord was intentionally included in the series through positioning; (2) 3D fluid-attenuated inversion recovery (3D FLAIR) series with 1 mm^3^ voxels; (3) conventional 3 mm (0.3 gap) axial 2D proton density/T2-weighted sequences with in-plane resolution 1 mm^2^; and (4) 3-mm sagittal 2D proton density/T2-weighted spinal cord sequences. No intravascular contrast was used.

MRI analyses. {#s1-9}
-------------

MRIs were reviewed by a neuroradiologist for unexpected findings. A single trained MRI analyst performed lesion counts, volumetrics, and cortical thickness analyses. The PI conducted spinal cord cross-sectional thickness and lesion occupancy analyses. Both were directed by the study neuroradiologist. Cerebral T2-hyperintense lesion volumes and maps were obtained using Lesion TOpology-preserving Anatomical Segmentation (Lesion-TOADS).^[@R15]^ FSL tools were used to create lesion-filled MP-RAGE images. SIENAX was used to determine cross-sectional whole-brain, white, and grey matter volumes.^[@R16]^ Whole-brain atrophy was determined using SIENA from the FSL package.^[@R16]^ Subcortical deep grey matter volumes were measured using FIRST.^[@R16]^ Cortical thickness, cortical volumetric segmentation, and analyses of these were performed with FreeSurfer ([surfer.nmr.mgh.harvard.edu/](http://surfer.nmr.mgh.harvard.edu/)) and its longitudinal processing stream.^[@R17]^ Spinal cord cross-sectional area was recorded at C1. An in-house estimation of the relative percent of the spinal cord from the foramen magnum to the lower edge of C7 occupied by MS lesions was devised for descriptive purposes. MRIs were graded for quality (good, fair, poor, and unusable). Poor and unusable scans were excluded from the analyses.

OCT. {#s1-10}
----

Participants underwent spectral domain OCT (Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA) in each eye after pharmacologic dilation (1% tropicamide and 0.5% proparacaine hydrochloride). Peripapillary and macular scans were obtained with Optic Disc Cube 200 × 200 and Macular Cube 512 × 128 protocols, respectively. OCTs were reviewed by an experienced neuro-ophthalmologist. Excluded scans had confounding findings, artifact, misalignment, or signal strength less than 7.

Clinical measures. {#s1-11}
------------------

Disability was captured by the EDSS. The same EDSS examiner was used for a given participant throughout the study to the extent possible. Mobility measures for ambulatory participants were Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale (MSWS-12) Questionnaire, and Activities-specific Balance Confidence (ABC) Questionnaire.^[@R18][@R19][@R20]^ Symbol Digit Modalities Test (SDMT) tested cognition.^[@R21]^ RAND 36-Item Short Form Health Survey assessed quality of life.^[@R22]^

Safety monitoring. {#s1-12}
------------------

AEs were categorized using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Unscheduled visits occurred for relapses, AEs, and early study termination visits. Safety monitoring laboratory tests (complete blood count and kidney and liver panels) were checked at each visit. The Columbia-Suicide Severity Rating Scale (C-SSRS) was administered at every visit. A 3-member data safety and monitoring board met every year.

Sample size, randomization, and blinding. {#s1-13}
-----------------------------------------

The study was powered for comparison of the primary outcome, PCBV, as estimated by Altmann et al.^[@R23]^ using an SD of 1.51 for SIENA atrophy, 2-year study length with yearly MRIs, and 60% effect size. A sample size of 23 per arm was needed to obtain 80% power and a significance of *p* \< 0.05. Projected enrollment was increased to allow for dropouts. Participants were assigned to LA or placebo in a 1:1 manner by the unblinded research pharmacist following a permutated block randomization based on EDSS ≤4.5 or \>4.5.^[@R13]^ All other study personnel were blinded to the treatment assignment. MRIs were labeled with additional randomly generated numbers during analyses to further reduce the risk of bias. Statistical analysis was performed by a blinded statistician for primary, secondary, and safety outcome measures.

Statistical methods. {#s1-14}
--------------------

Intention-to-treat (ITT) analysis used linear mixed models to evaluate the effect of LA on annualized PCBV. Mixed models were used to adjust for within-participant serial correlation, to account for the repeated measurements of the longitudinal design, and to include all study participants. Models were corrected for participant age, sex, and MS duration with standard model diagnostics to identify overly influential leverage points. Multiple comparisons were accounted for using the Holm-Sidak correction within the study outcome domains. Outlier data points were identified through standard diagnostic techniques using combinations of data point leverage, individual residuals, and Cook distance to identify overly influential observations and exclude them from baseline and 2-year change analyses. Data from participants taking a reduced dose of LA (n = 2) were not handled differently in outcome analyses as their limited number made subgroup assessment intractable. Mixed-model results are reported as rates of change with variance represented by the standard errors of the coefficient estimates (SEEs). Post hoc analysis of the primary outcome measure was conducted adding the baseline whole-brain volume and baseline T2-lesion volume as covariates to the model. All analyses were performed using R 3.3.1 with additional utility from the lme4 package.^[@R24],[@R25]^

RESULTS {#s2}
=======

Of the 54 consented and randomized, 51 participants (27 LA and 24 placebo) took at least 1 dose of study drug and were included in the ITT analyses ([figure 1](#F1){ref-type="fig"}). Forty-six participants completed the study (22 LA and 24 placebo). The 5 dropouts in the LA cohort were for reasons of claustrophobia during MRI, prolonged nausea and vomiting which resolved on cessation of LA, and significant concurrent illness (prostate cancer, proteinuria, and worsening renal function). Because the dropout with claustrophobia did not complete the baseline MRI, the LA cohort ITT sample size for PCBV was 26 ([figure 1](#F1){ref-type="fig"}).

![2010 CONSORT flow diagram](NEURIMMINFL2017012526FF1){#F1}

Baseline demographics are presented in [table 1](#T1){ref-type="table"}. The LA and control cohorts were overall matched for age, sex, MS duration, education, and disability. There were no significant differences between treatment arms (all *p* \> 0.05). [Table 2](#T2){ref-type="table"} presents the baseline values of the main study outcome measures by study arms. The LA cohort had a significantly larger baseline whole-brain (*p* = 0.004) and total deep grey matter volumes (*p* = 0.042). Controls had larger baseline normalized T2-lesion volumes.

###### 

Baseline demographics and clinical characteristics of study participants by treatment (n = 51)

![](NEURIMMINFL2017012526TT1)

###### 

Baseline differences between study outcome measures (mean, SD)

![](NEURIMMINFL2017012526TT2)

Compliance with study drug was 87% by pill counts. Two participants took a halved dose of LA per protocol for the majority of the study, one each for gastritis and elevated alkaline phosphatase levels.

Rate of brain atrophy and secondary imaging outcomes. {#s2-1}
-----------------------------------------------------

After 2 years, participants taking LA had significantly less annualized PCBV (−0.21% \[SEE 0.14\]) than controls (−0.65% \[SEE 0.10\], *p* = 0.002), with the beneficial effect size of LA treatment observed to be a 0.44% ± 0.29% improvement in the rate of whole-brain atrophy (95% confidence interval \[CI\] 0.157--0.727). This change corresponds to a 68% reduction in the rate of brain atrophy in LA vs placebo ([figure 2A](#F2){ref-type="fig"}, [table 3](#T3){ref-type="table"}). In post hoc analysis, baseline whole-brain volume was not associated with any of the other controlling covariates (age, sex, and disease duration), nor did it affect the differences in PCBV between the study cohorts. Likewise, T2-lesion volume change over the study period was not associated with any of the correcting covariates, including baseline T2-lesion volume. Individual 2-year changes in PCBV for LA (−0.45% \[SEE 0.71\]) vs controls (−1.31% \[SEE 1.10\], *p* = 0.001) in study completers are shown ([figure 2B](#F2){ref-type="fig"}). Brain segmentation and OCT did not reveal significant differences in annualized rates of change between study arms; the increase in T2-lesion volume in the LA cohort was almost but not significantly different from controls (414.6 \[SEE 201.2\] vs 33.1 \[SEE 134.7\], *p* = 0.058, [table 3](#T3){ref-type="table"}).

![Differences in brain atrophy at 2 years between LA and control cohorts\
Annualized percent change brain volume (PCBV) between LA and placebo cohorts using intention-to-treat analysis of 51 participants with secondary progressive MS (A). Two-year PCBV from study completers is shown and demonstrates significantly less PCBV in the LA cohort (n = 22, −0.45% \[SEE 0.71\]) than controls (n = 24, −1.31% \[SEE 1.10\], *p* = 0.001, B). LA = lipoic acid; SEE = standard errors of the coefficient estimate.](NEURIMMINFL2017012526FF2){#F2}

###### 

Study outcomes

![](NEURIMMINFL2017012526TT3)

Clinical outcomes. {#s2-2}
------------------

Among clinical outcomes, the LA cohort demonstrated an improvement in the T25FW that was almost but not significantly different from controls (−0.535 \[SEE 0.358\] vs 0.137 \[SEE 0.247\], 95% CI −1.37 to 0.03, *p* = 0.060).

AEs. {#s2-3}
----

AEs are presented in table e-1. Numbers of AEs were similar between LA and controls (80 and 68, respectively, *p* = 0.87), with 6 serious AEs (SAEs) each. More GI upset (14 \[SD 17%\] vs 2 \[SD 3%\], *p* = 0.007) and fewer falls (12 \[SD 15%\] vs 26 \[SD 38%\], *p* = 0.03) occurred in the LA cohort. One LA participant developed a nonbothersome vesicular rash, similar to a previously reported one, that resolved within 6 weeks of study completion.^[@R11]^ One relapse occurred in each study cohort, neither affecting the subsequent EDSS examination. There was no new suicidality by C-SSRS, and no differences between cohorts in new laboratory abnormalities; however, only those taking LA required a dose reduction per protocol (n = 2). The SAE thought directly related to LA was vomiting and dehydration requiring hospitalization which resolved once stopping LA. Notable AEs leading to dropout were one LA patient with baseline elevated creatinine progressing to renal failure and another with proteinuria due to glomerulonephritis. A consulting nephrologist did not think that the 2 AEs were related to LA. AEs are discussed further in appendix e-2.

DISCUSSION {#s3}
==========

This two-year, randomized, double-blind, placebo-controlled pilot trial demonstrated a significant reduction in the primary outcome measure of the annualized rate of whole-brain atrophy by SIENA in people with SPMS taking 1,200 mg daily oral LA. The annualized PCBV reduction was not influenced by the planned covariates of age, sex, and disease duration, nor by the post hoc additions of baseline brain and T2-lesion volumes. There was a suggestion of improved T25FW time, and there were fewer falls in the LA cohort. Overall LA was safe, well tolerated, had high compliance, and had no unexpected deleterious AEs or SAEs attributed to LA.

The reduction in the brain atrophy rate compares favorably with a large phase 3 trial of ocrelizumab (n = 731), reporting a 17.5% reduction in the whole-brain atrophy rate over 120 weeks.^[@R26]^ In contrast to the present study, the ocrelizumab trial included only primary progressive MS patients with more men (51% vs 39%) who were younger (45 vs 59 years), had shorter disease duration (6.5 vs 30 years), and less disability (EDSS 4.7 vs 5.4). The ocrelizumab trial limited inclusion to those with inflammatory CSF, a characteristic not assessed in this study. Other disease-modifying therapy trials in progressive MS populations have not demonstrated robust changes in brain atrophy rates or have not used this outcome measure.^[@R27][@R28][@R29]^

The PCBV reduction was for the whole-brain assessment by SIENA, a robust registration--based longitudinal atrophy measure.^[@R30]^ Brain segmentation did not reveal specific brain compartments responsible for differential atrophy rates. One explanation is that the sample size calculation was based on SIENA and not on segmentation methods, techniques which produce heterogeneous results and require larger samples.^[@R30]^ Segmented volumes may be more prone to physiologic factors including hydration status and positioning than whole-brain measurements.^[@R31]^ Alternatively, the PCBV reduction may come from an effect common across all brain tissues. Study replication in a larger sample will clarify the nature of LA\'s atrophy effects.

The suggestion of greater increase in T2-lesion volume in the LA cohort is of uncertain significance. The increase may be real and thus represent potential harmful effects of LA, may represent physiologic changes other than due to MS, may result from MR postprocessing quality issues, or may not be different from placebo.^[@R15]^ Further evaluation is warranted.

Overall, LA was safe and well tolerated. Laboratory abnormalities were limited to asymptomatic elevations in alkaline phosphatase which improved on cessation of LA. Although there were no unexpected AEs or SAEs clearly attributable to LA, the renal failure and glomerulonephritis cases raise concern. Previous studies with LA have not reported renal dysfunction.^[@R9][@R10][@R11]^ Even so, closer renal function monitoring is prudent for future LA studies and suggests caution in recommendation of this dose of LA before further evaluations.

A potential study confounder of which the authors were unaware when planning the study was the presence of quercetin (8.6 mg daily) in the placebo. Quercetin, like other bioflavonoids, is biologically active. Although conflicting reports exist, Van Beek et al. found that 10 mg daily oral quercetin increased inflammation and exacerbated active and passive EAE in mice. This raises the possibility that in the present study, quercetin could have worsened the controls and exaggerated the effects of LA.^[@R32]^ The calculated analogous human dose to the Van Beek study is 2 g, orders of magnitude greater than the placebo capsules.^[@R33]^ Therefore, while unlikely to have affected present study outcomes, future studies should avoid quercetin to exclude this possibility.

Other study limitations relate primarily to the small sample size of this pilot study with resulting loss of power to detect clinical and secondary imaging outcomes as has been discussed. In light of this, the very robust reduction in the brain atrophy rate might be viewed with skepticism, although the comparable atrophy rate of the controls to other untreated SPMS cohorts lends credence to the findings.^[@R23],[@R34]^ Baseline differences in brain volume or T2-lesion volume existed between study cohorts; however, post hoc analyses did not find an influence of these differences on study outcomes. A larger sample size in future studies should correct for baseline imbalances. Finally, as a contrast agent was not used, baseline and ongoing differences in inflammatory activity on MRI are unknown.

This 2-year pilot trial of 1,200 mg daily LA demonstrated significant reduction in PCBV in patients with SPMS over controls. The small sample size precluded detection of clinical benefits, although there was suggestion of improved walking times and significantly fewer falls. Although LA was overall safe and well tolerated, future studies need to establish clinical benefits and explore mechanisms of action of LA in progressive MS.

Supplemental data at [Neurology.org/nn](10.1212/NXI.0000000000000374)
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CI
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EAE

:   experimental autoimmune encephalomyelitis
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:   gastrointestinal
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